EP0568631A4 - Monoclonal antibodies to elam-1 and their uses. - Google Patents

Monoclonal antibodies to elam-1 and their uses.

Info

Publication number
EP0568631A4
EP0568631A4 EP92905123A EP92905123A EP0568631A4 EP 0568631 A4 EP0568631 A4 EP 0568631A4 EP 92905123 A EP92905123 A EP 92905123A EP 92905123 A EP92905123 A EP 92905123A EP 0568631 A4 EP0568631 A4 EP 0568631A4
Authority
EP
European Patent Office
Prior art keywords
elam
monoclonal antibodies
monoclonal
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP92905123A
Other languages
German (de)
French (fr)
Other versions
EP0568631A1 (en
Inventor
Elisabeth Wayner
Mary L Phillips
Jeffrey L Winkelhake
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytel Corp
Original Assignee
Cytel Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytel Corp filed Critical Cytel Corp
Publication of EP0568631A1 publication Critical patent/EP0568631A1/en
Publication of EP0568631A4 publication Critical patent/EP0568631A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP92905123A 1991-01-24 1992-01-23 Monoclonal antibodies to elam-1 and their uses. Withdrawn EP0568631A4 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US64587891A 1991-01-24 1991-01-24
US645878 1991-01-24
US73303391A 1991-07-22 1991-07-22
US733033 1991-07-22

Publications (2)

Publication Number Publication Date
EP0568631A1 EP0568631A1 (en) 1993-11-10
EP0568631A4 true EP0568631A4 (en) 1995-04-05

Family

ID=27094802

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92905123A Withdrawn EP0568631A4 (en) 1991-01-24 1992-01-23 Monoclonal antibodies to elam-1 and their uses.

Country Status (11)

Country Link
EP (1) EP0568631A4 (en)
JP (1) JPH06505253A (en)
AU (1) AU1269092A (en)
CA (1) CA2100681A1 (en)
IE (1) IE920206A1 (en)
IL (1) IL100764A0 (en)
NO (1) NO932672L (en)
NZ (1) NZ241399A (en)
OA (1) OA09809A (en)
SK (1) SK77393A3 (en)
WO (1) WO1992012729A1 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646123A (en) * 1991-06-10 1997-07-08 Alberta Research Council Time dependent administration of oligosaccharide glycosides related to blood group determinants having a type I or type II core structure in reducing inflammation in a sensitized mammal arising form exposure to an antigen
US6093399A (en) * 1992-03-05 2000-07-25 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
US5660827A (en) * 1992-03-05 1997-08-26 Board Of Regents, The University Of Texas System Antibodies that bind to endoglin
US5877289A (en) * 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US6004555A (en) * 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US6036955A (en) * 1992-03-05 2000-03-14 The Scripps Research Institute Kits and methods for the specific coagulation of vasculature
EP1306095A3 (en) * 1992-03-05 2003-06-25 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5728802A (en) * 1992-05-06 1998-03-17 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelium leukocyte adhesion molecule 1 (ELAM-1)
US5643873A (en) * 1992-05-06 1997-07-01 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelial leukocyte adhesion molecule 1
US5648458A (en) * 1992-05-06 1997-07-15 Affymax Technologies N.V. Peptides and compounds that bind to ELAM-1
EP0602290B1 (en) * 1992-12-04 1999-08-25 ConjuChem, Inc. Antibody-conjugated Hepatitis B surface antigen and use thereof
US5723116A (en) * 1995-01-06 1998-03-03 University Of South Florida Decreased mortality of severe acute pancreatitis following proximal cytokine blockade
AU6155896A (en) * 1995-06-07 1996-12-30 Cytel Corporation Humanized antibodies to e-selectin
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
US6524553B2 (en) 1998-03-31 2003-02-25 Bristol-Myers Squibb Pharma Company Quinolone vitronectin receptor antagonist pharmaceuticals
US6548663B1 (en) 1998-03-31 2003-04-15 Bristol-Myers Squibb Pharma Company Benzodiazepine vitronectin receptor antagonist pharmaceuticals
WO2000002587A1 (en) 1998-07-13 2000-01-20 Board Of Regents, The University Of Texas System Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
US6818213B1 (en) 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
US6511648B2 (en) 1998-12-18 2003-01-28 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6511649B1 (en) 1998-12-18 2003-01-28 Thomas D. Harris Vitronectin receptor antagonist pharmaceuticals
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6794518B1 (en) 1998-12-18 2004-09-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
WO2000035887A2 (en) 1998-12-18 2000-06-22 Du Pont Pharm Co Vitronectin receptor antagonist pharmaceuticals
US7030219B2 (en) 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
EP2328919A2 (en) * 2008-08-25 2011-06-08 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
WO2018203545A1 (en) 2017-05-02 2018-11-08 国立研究開発法人国立精神・神経医療研究センター Method for predicting and evaluating therapeutic effect in diseases related to il-6 and neutrophils
US11692037B2 (en) 2017-10-20 2023-07-04 Hyogo College Of Medicine Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
MX2022009130A (en) 2020-01-24 2022-08-22 Pfizer Anti-e-selectin antibodies, compositions and methods of use.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005786A1 (en) * 1988-11-14 1990-05-31 Brigham And Women's Hospital Cloned genes which encode elam-1 and fusion proteins thereof, the protein products expressed therefrom, pharmaceutical compositions and the use thereof
WO1990013300A1 (en) * 1989-04-28 1990-11-15 Biogen, Inc. ENDOTHELIAL CELL-LEUKOCYTE ADHESION MOLECULES (ELAMs) AND MOLECULES INVOLVED IN LEUKOCYTE ADHESION (MILAs)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68927188T2 (en) * 1988-11-14 1997-04-24 Brigham & Womens Hospital ANTIBODIES, SPECIFIC TO ELAM-1 AND THEIR USE

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005786A1 (en) * 1988-11-14 1990-05-31 Brigham And Women's Hospital Cloned genes which encode elam-1 and fusion proteins thereof, the protein products expressed therefrom, pharmaceutical compositions and the use thereof
WO1990013300A1 (en) * 1989-04-28 1990-11-15 Biogen, Inc. ENDOTHELIAL CELL-LEUKOCYTE ADHESION MOLECULES (ELAMs) AND MOLECULES INVOLVED IN LEUKOCYTE ADHESION (MILAs)

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
C. BENJAMIN ET AL.: "A blocking monoclonal antibody to endothelial-leukocyte adhesion molecule-1 (ELAM1).", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 171, no. 1, 31 August 1990 (1990-08-31), DULUTH MN, USA, pages 348 - 353 *
M. BEVILACQUA ET AL.: "Identification of an inducible endothelial-leukocyte adhesion molecule.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 84, no. 24, December 1987 (1987-12-01), WASHINGTON DC, USA, pages 9238 - 9242 *
N. GRABER ET AL.: "T cells bind to cytokine-activated endothelial cells via a novel, inducible sialoglycoprotein and endothelial leukocyte adhesion molecule-1.", THE JOURNAL OF IMMUNOLOGY, vol. 145, no. 3, 1 August 1990 (1990-08-01), BALTIMORE MD, USA, pages 819 - 830 *
S. WELLICOME ET AL.: "A monoclonal antibody that detects a novel antigen on endothelial cells that is induced by tumor necrosis factor, IL-1, or lipopolysaccharide.", THE JOURNAL OF IMMUNOLOGY, vol. 144, no. 7, 1 April 1990 (1990-04-01), BALTIMORE MD, USA, pages 2558 - 2565 *
See also references of WO9212729A1 *

Also Published As

Publication number Publication date
SK77393A3 (en) 1994-12-07
NO932672L (en) 1993-09-23
AU1269092A (en) 1992-08-27
IL100764A0 (en) 1992-09-06
WO1992012729A1 (en) 1992-08-06
OA09809A (en) 1994-04-15
IE920206A1 (en) 1992-07-29
EP0568631A1 (en) 1993-11-10
CA2100681A1 (en) 1992-07-25
JPH06505253A (en) 1994-06-16
NZ241399A (en) 1994-06-27
NO932672D0 (en) 1993-07-23

Similar Documents

Publication Publication Date Title
EP0568631A4 (en) Monoclonal antibodies to elam-1 and their uses.
EP0627932A4 (en) Novel antibody construct.
IL101690A0 (en) Antibodies and methods utilizing the same
IL111926A0 (en) Humanized antibodies and uses thereof
GB9412166D0 (en) Retargetting antibodies
EP0804235A4 (en) Antibodies to p-selectin and their uses
EP0683675A4 (en) Human monoclonal antibodies to cytomegalovirus.
EP0285511A3 (en) Monoclonal antibodies and their uses
EP0506523A3 (en) Monoclonal antibodies
GB9204928D0 (en) Monoclonal antibody production
ZA898499B (en) Anti-fucosylcermiade monoclonal antibody
GB2309459B (en) Antibodies to fungal antigens
ZA89258B (en) Monoclonal antibodies
ZA92468B (en) Monoclonal antibodies to ELAM-1 and their uses
GB9223676D0 (en) Modified antibodies
GB2207921B (en) Monoclonal antibody to omega-gliadin and hybridoma thereof
HU9503156D0 (en) Antibodies to p-selectin and their uses
EP0547631A3 (en) Antibody expression vector and antibodies produced thereby
EP0654532A4 (en) Antimucoglycoprotein monoclonal antibody.
GB9115010D0 (en) Antibody
ZA912136B (en) Anti-oncostatin m monoclonal antibodies
IL103758A0 (en) Tumor specific monoclonal antibodies
GB9118013D0 (en) Monoclonal antibodies and their use
IE900593L (en) Monoclonal antibodies
IE900922L (en) Monoclonal antibody

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19930813

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL

RBV Designated contracting states (corrected)

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

RHK1 Main classification (correction)

Ipc: A61K 39/395

A4 Supplementary search report drawn up and despatched

Effective date: 19950215

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL

17Q First examination report despatched

Effective date: 19970411

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19970822